

Expression of Interest from the Industry for Developing Nucleic Acid Sequencing Reagents and Disease Specific Panels

Date of Release: 13th April 2023

Reference: CSIR-IGIB/BDMG/2023/EOI/02

The last two decades have witnessed rapid advancements in the development, adoption and implementation of genomic technologies in biological / bio-medical research and application. The rapid advances in sequencing technologies along with the drastic decline in cost have allowed faster, affordable and accurate genome sequencing. Further, genome sequencing technologies have made it possible to understand population and personal genomes at a scale not possible before. The power of these technologies were also well demonstrated during the COVID-19 pandemic.

The global DNA sequencing market is projected to grow rapidly in the next few decades. This growth would be fuelled largely by the introduction of newer sequencing platforms, which would have much higher throughput, speed and accuracy. The DNA sequencing consumables, including molecular reagents, enzymes and kits are expected make up almost half of the revenue share in this market. The demand for new DNA sequencing consumables is ever increasing and there is ample scope for improvement and innovation in this space.

Towards this CSIR-IGIB is inviting Expression of Interest (EOI) from commercial organisations with specialised know-how knowledge in the biological kit development sector indigenous infrastructure and production capacity for sharing of expertise, knowledge and resources for co-development of nucleic acid sequencing reagents and disease panels. Selected partners would be able to avail suitable laboratory space and access high-end equipments at IGIB following the CSIR rules and regulations. The aim of the partnership would be towards expediting the Research and Development and accelerating solutions that could be useful for the nation and also serve global needs.

About CSIR-IGIB: CSIR Institute of Genomics and Integrative Biology (CSIR-IGIB) is a constituent national laboratory under the Council of Scientific and Industrial Research (CSIR, India) and a premier institution engaged in research of national importance in the areas of genomics, genome biology, molecular medicine and bioinformatics. The institute has a stated mission to translate concepts developed in basic biological research to commercially viable technologies for health care.

Interested organisations may send an **Expression of Interest** to the following address:

The Director,

CSIR Institute of Genomics and Integrative Biology,

Attn: Head-Business Development,

Sukdev Vihar, Mathura Road,

New Delhi 110 025

Email: director@igib.res.in , headbdmg@igib.res.in

For more details, visit www.igib.res.in